Many thanks @chucktodd for hosting me on @MeetThePress with @ellisonbarber discussing how we navigate issues around JnJ vaccine and urgency to vaccinate ahead of an accelerating B.1.1.7 variant 
Presumably the pause is to compare notes with European and UK regulators for both adenovirus vectored vaccines AZOx and JnJ. I said possible outcome would be if we could identify a specific at risk population say premenopausal women with a second risk factor such as BC, smoking
Then in this case we could redirect JnJ away from this group. I also stated more philosophically that this is a predictable consequence of only focusing on innovative vaccine technologies. We made some great vaccines but introduced some unnecessary risks and as a consequence..
We have two mRNA vaccines which are great vaccines but can’t be scaled to produce to 5 billion doses needed for LMICs, or adenovirus vectored vaccines which were never scaled and now difficult to navigate these safety flares. We needed more “old school” recomb protein vaccines..
Our vaccine being scaled in India to 1.2 billion doses , but we need US Govt to take more ownership and help us make another 3-4 billion doses.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
